Table 5.
Select trials in relapsed/refractory multiple myeloma.
| Clinical trial | Number of patients | Treatment regimen | Median age (years) | Median follow up (months) | Progression-free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|
| CANDOR91 | 466 | KdD vs Kd | 64 | 27.8 | 28.6 vs 15.2 | NR in both groups |
| ICARIA_MM94 | 307 | Isa-Pd vs Pd | 67 | 11.6 | 11.5 vs 6.5 | NR in both groups |
| IKEMA90 | 302 | Isa-Kd vs Kd | 64 | 44 | 35.7 vs 19.1 | NR in both groups |
| APOLLO95 | 304 | Pom-Dara-Dex vs Pom-Dex | 67 | 16.9 | 12.4 vs 6.9 | NR in both groups |
| ELOQUENT-296,97 | 646 | Elotuzumab-Rd vs Rd | 66 | 70.6 | 19.4 vs 14.9 | 48.3 vs 39.6 |
| OPTIMISMM98 | 559 | Pom-Vd vs Vd | 67 | 15.9 | 11.2 vs 7.1 | NR in both groups |
| POLLUX92,93 | 569 | DRd vs Rd | 65 | 54.8 | 45 vs 17.5 | 67.6 vs 51.8* |
| CASTOR99 | 498 | D-Vd vs Vd | 64 | 47 | 16.7 vs 7.1 | 49.6 vs 38.5∞ |
Abbreviations: KdD, Carfilzomib, dexamethasone, daratumumab; Kd, Carfilzomib, dexamethasone; Pom-Dex, Pomalidomide, dexamethasone; Isa-Pd, Isatuximab, pomalidomide, dexamethasone; Pd, pomalidomide, dexamethasone; Isa-Kd, Isatuximab, carfilzomib, dexamethasone; Pom-Dara-Dex, Pomalidomide, daratumumab, dexamethasone; Rd, Lenalidomide, dexamethasone; Pom-VD, pomalidomide, bortezomib, dexamethasone; Vd, Bortezomib, dexamethasone; NR, Not reached; DRd, Daratumumab, lenalidomide, dexamethasone; D-Vd, Daratumumab, bortezomib, dexamethasone.
*Median follow up: 79.7 months.
∞Median follow up: 72.6 months.